Developer docs
API playgroundTry for free, no card

Search company profiles

Hemogenix®

Full company profile

uuid000mpc2

Namestring
Hemogenix®
Legal namestring
Hemogenix, Inc.
Websiteurl
hemogenix.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Hemogenix® is a contract research organization (CRO) founded in 2000 and headquartered in Colorado Springs, Colorado, specializing in proprietary in vitro toxicity testing and cell biology services for the biopharmaceutical industry. The company's technology is built on Suspension Expansion Culture™ (SEC™) Technology coupled with ATP bioluminescence signal detection (using third-party Promega reagents such as CellTiter-Glo®), and is delivered through eleven tissue- and cell-type-specific assay platforms: HALO®-Tox HT (hematotoxicity), ImmunoGlo™ (immunotoxicity), MSCGlo™-Tox HT (mesenchymal stem cells), HepatoGlo™-Tox HT (hepatotoxicity), CardioGlo™-Tox HT (cardiotoxicity), RenalGlo™-Tox HT (nephrotoxicity), NeuroGlo™-Tox HT (neurotoxicity), SkinGlo™-Tox HT (skin toxicity), EpiGlo™-Tox HT (intestinal toxicity), CellaGlo™-Tox HT (tumor cells), and STEMGlo™-Tox HT (ES/iPS/transformed cell lines). These are integrated into the ComparaTOX™ multi-tissue comparative platform (available in HT and FS formats) and supplemented by HemaToxFlow™ (flow cytometry-based hematotoxicity), cellular therapy potency and QC assays (HALO® SC-IPS, MSCGlo™ SC-IPS, STEMpredict™, HALO® QC, HALO® TE, HALO® PMT), mechanism-of-action studies, IND-enabling assays, and a Nanoparticle In Vitro Toxicity Panel. HALO®-Tox HT and HALO® SC-IPS are validated according to FDA Bioanalytical Method Validation Guidelines, have FDA Master Files, and HALO®-Tox HT shows 82% in vitro-to-in vivo concordance (Olaharski et al., 2009) and validation against the NIH/ICCVAM Registry of Cytotoxicity Prediction Model.

The company serves small, medium, and large biopharmaceutical companies, with disclosed penetration of more than half of the top 50 global biopharma, and reports that study results have been included in numerous FDA IND applications. Customers engage HemoGenix on a fee-for-service contract basis; there is no subscription or recurring revenue model. Three study formats are offered: a customized full-service study with Study Plan, Phase I Draft Report, Phase II Final Report, and QA audit (suitable for IND submissions, billed under multi-year contract structures); a rapid toxicity study delivering raw data and protocol in an Excel workbook (pay-as-you-go); and a high-throughput screening module priced in multiples of 5 compounds per tissue (pay-as-you-go). Distribution is direct (one-on-one consultation, email/phone engagement at contractresearch@hemogenix.com) and indirect, through listing on the Scientist.com and Science Exchange pharmaceutical outsourcing marketplaces and the Thermo Fisher Scientific Service Marketplace.

The company's go-to-market is sales-led and account-based, leveraging peer-reviewed publications, scientific conference presentations (AABB, ISCT, Society of Toxicology, Cord Blood Symposium), white papers, and marketplace presence to reach biopharma procurement and preclinical safety teams. Preferred Cell Systems™ operates as a sister company that sells the same proprietary assay platforms as kit products ("Assays-in-a-Box™") and licenses them to sponsors who prefer in-house testing, extending revenue capture beyond pure service work. The company has received two NCI SBIR grants (2002 and 2005) to develop the HALO®-Tox HT platform and subsequent assay portfolio. Headcount is reported at 1–10 employees and revenue is not publicly disclosed.

Short descriptiontext

Hemogenix® is a Colorado Springs-based contract research organization that provides proprietary ATP bioluminescence-based in vitro toxicity testing and cell biology services to biopharmaceutical companies, including more than half of the top 50 global biopharma firms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersColorado Springs, United States
HQ citystring
Colorado Springs
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro toxicity testing, contract research services, cell biology assays, drug safety screening, stem cell potency testing
Industry3 codes
PRIMARYHLAFAMAC
Hematology & Coagulation Laboratories
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services (CRO)
TypeProfessional Services
Description

HemoGenix® operates as a Contract Research Organization (CRO) providing fee-for-service in vitro toxicity testing and cell biology research services. Services are delivered through customized study contracts with biopharmaceutical companies, with study formats ranging from rapid toxicity screening reports to complete IND-enabling full-service studies with QA audit. Revenue is generated on a per-study basis with no recurring subscription model.

hemogenix.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details3 tiers
1Customized Full-Service Study Quote
ModelOtherBilling cadenceMulti-year contract
Notes

Full-service contract study including Study Plan, Phase I Draft Report, Phase II Final Report, and QA audit. Suitable for IND applications. Price is quoted per-study based on study parameters.

hemogenix.com
2Rapid Toxicity Study Quote
ModelOtherBilling cadencePay-as-you-go
Notes

Streamlined study delivering raw data, protocol, and graphical results in a single Excel Workbook. No formal text report or QA audit. More cost-effective than full-service study.

hemogenix.com
3High-Throughput Toxicity Screening Quote (ComparaTOX™ HT)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Set cost toxicity screening for multiples of 5 compounds tested on specific tissues. Data provided in Excel Workbook only. Part of the ComparaTOX™ HT Platform for rapid compound ranking.

hemogenix.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 23 records shown
1HALO®-Tox HT
Description

Proprietary high-throughput hematotoxicity screening and testing platform using Suspension Expansion Culture™ (SEC™) Technology and ATP bioluminescence

hemogenix.com
+22 more records
Core offering1 text field

Hemogenix® is a contract research organization that provides in vitro toxicity testing and cell biology research services to biopharmaceutical companies. The company uses proprietary ATP bioluminescence-based assay platforms built on Suspension Expansion Culture™ (SEC™) Technology to deliver high-throughput hematotoxicity, immunotoxicity, hepatotoxicity, cardiotoxicity, neurotoxicity, renal, skin, intestinal, and tumor cell toxicity testing, along with cell therapy quality and potency testing, IND-enabling studies, mechanism of action studies, and nanoparticle toxicity panels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 82% concordance between in vitro HALO®-Tox HT IC50 values and in vivo rat toxicity data
+4 more records
Product overview1 text field

Hemogenix® is a contract research organization specializing in in vitro toxicity testing and cell biology services. The company offers a comprehensive portfolio of proprietary ATP bioluminescence-based assay platforms, with HALO®-Tox HT as the foundational high-throughput hematotoxicity platform launched in 2002. The product ecosystem includes multiple tissue-specific toxicity testing platforms (ImmunoGlo™, MSCGlo™, HepatoGlo™, CardioGlo™, RenalGlo™, NeuroGlo™, SkinGlo™, EpiGlo™, CellaGlo™, STEMGlo™) that share the same standardized ATP bioluminescence readout technology, enabling direct comparison of drug toxicity across different tissues. The ComparaTOX™ Platform integrates all these assays for multi-tissue comparative toxicity screening in HT (high-throughput) and FS (full service) formats. Additional offerings include HemaToxFlow™ for flow cytometric analysis, potency assays (HALO® SC-IPS, MSCGlo™ SC-IPS, STEMGlo™ SC-IPS), quality control assays (STEMpredict™, HALO® QC), mechanism of action studies, nanoparticle toxicity testing, IND-enabling assay services, and in vivo to in vitro testing extensions. The sister company Preferred Cell Systems™ provides assay kits for in-house testing.

Product and service19 records
1HALO®-Tox HT Hematotoxicity Testing
CategoryIn Vitro Toxicity Testing
Description

Proprietary high-throughput hematotoxicity screening and testing platform for stem and progenitor cell toxicity assessment, available in 96- and 384-well formats and validated according to FDA Bioanalytical Method Validation Guidelines.

2ImmunoGlo™ Immunotoxicity Testing
CategoryIn Vitro Toxicity Testing
Description

ATP bioluminescence assay platform for immune cell proliferation, T-cell and B-cell specific cytotoxicity testing, and 1- or 2-way mixed lymphocyte reactions used for immunotoxicity screening and testing.

3HepatoGlo™-Tox HT Hepatotoxicity Testing
CategoryIn Vitro Toxicity Testing
Description

Proprietary hepatotoxicity testing platform based on ATP bioluminescence readout for drug-induced liver toxicity (DILI) using various hepatocyte sources including iPS-derived and cryopreserved primary cells.

4CardioGlo™-Tox HT Cardiotoxicity Testing
CategoryIn Vitro Toxicity Testing
Description

In vitro cardiotoxicity testing platform using ATP bioluminescence to measure cardiomyocyte viability, supporting multiple cardiomyocyte sources and species for high-throughput compound screening.

5NeuroGlo™-Tox HT Neurotoxicity Testing
CategoryIn Vitro Toxicity Testing
Description

Proprietary neurotoxicity screening and testing platform using ATP bioluminescence with iPS-derived human neural cells including GABA neurons and motor neurons, available in 96- or 384-well formats.

6RenalGlo™-Tox HT Renal Toxicity Testing
CategoryIn Vitro Toxicity Testing
Description

In vitro renal/nephrotoxicity testing platform using ATP bioluminescence with renal epithelial cell types from medulla, glomerulus, distal and proximal tubules, and cortex, supporting multiple species.

7SkinGlo™-Tox HT Skin Toxicity Testing
CategoryIn Vitro Toxicity Testing
Description

In vitro skin toxicity testing platform using ATP bioluminescence with dermal fibroblasts and microvascular endothelial cells from multiple species.

8EpiGlo™-Tox HT Intestinal Toxicity Testing
CategoryIn Vitro Toxicity Testing
Description

In vitro intestinal/gut toxicity testing platform using ATP bioluminescence for primary human intestinal cell populations including epithelial cells and myofibroblasts.

9MSCGlo™-Tox HT Mesenchymal Cell Toxicity Testing
CategoryIn Vitro Toxicity Testing
Description

Standardized and validated ATP bioluminescence toxicity assay specifically designed for mesenchymal stem/stromal cells (MSCs), measuring functional viability based on intracellular ATP for toxicity testing and high-throughput screening.

10CellaGlo™-Tox HT Tumor Cell Testing
CategoryIn Vitro Toxicity Testing
Description

In vitro testing platform for drugs affecting tumor cells using ATP bioluminescence technology.

11STEMGlo™-Tox HT Stem Cell Toxicity Testing
CategoryIn Vitro Toxicity Testing
Description

In vitro toxicity testing platform for transformed cell lines, embryonic stem (ES) cells, and induced pluripotent stem (iPS) cells using ATP bioluminescence.

12ComparaTOX™ Multi-Tissue Comparative Toxicity Platform
CategoryIn Vitro Toxicity Testing
Description

Multi-tissue comparative toxicity testing platform that integrates all Hemogenix ATP bioluminescence-based assays (HALO, ImmunoGlo, MSCGlo, HepatoGlo, CardioGlo, RenalGlo, NeuroGlo, SkinGlo, EpiGlo, CellaGlo, STEMGlo), enabling direct comparison of drug toxicity across different tissues and species. Available in HT and full-service formats.

13Cell Therapy Quality & Potency Testing
CategoryCell Therapy Quality Testing
Description

Potency and quality testing service for hematopoietic and mesenchymal stem cells, including Identity, Purity, and Strength (SC-IPS) assays for cord blood, bone marrow, and mobilized peripheral blood; validated per FDA and EMA guidelines for regenerative medicine products.

14IND-Enabling Assay Services
CategoryRegulatory Assay Services
Description

Contract research service providing standardized and validated assay results with measurement assurance parameters suitable for IND applications to the FDA. Results from Hemogenix studies have been included in numerous IND applications.

15Mechanism of Action Studies
CategoryMechanism of Action Studies
Description

Comprehensive mechanism of action study services including flow cytometry, membrane integrity assays, micronucleus assay, soft agar assay, chemotaxis/migration assays, cytokine production/release, kinase/protease assays, mitochondrial dysfunction, oxidative stress assays, and CYP450 assays.

16Nanoparticle In Vitro Toxicity Panel
CategoryIn Vitro Toxicity Testing
Description

Comprehensive nanoparticle toxicity testing panel providing alternatives to NCI Nanoparticle Characterization Laboratory (NCL) recommended assays, using superior primary human cells instead of animal cells or transformed cell lines.

17In Vivo to In Vitro Testing
CategoryIn Vitro Toxicity Testing
Description

Service extending preclinical animal studies by preparing organs and tissues for in vitro culture systems to detect cellular responses not detectable by normal pharmacological tests, achieving approximately 80% concordance with in vivo results.

18HemaToxFlow™ Flow Cytometric Hematotoxicity Assay
CategoryIn Vitro Toxicity Testing
Description

In vitro flow cytometric assay for determining potential hematotoxicity of stem and progenitor cells from human and mouse tissues, using CD markers to define specific differentiated cell populations as an alternative to colony-forming cell (CFC) assays.

19Contract Research Services (CRO)
CategoryContract Research Services
Description

Full-service contract research organization offering customized full-service, rapid toxicity, and high-throughput screening study workflows covering hematotoxicity, immunotoxicity, hepatotoxicity, cardiotoxicity, neurotoxicity, renal toxicity, mesenchymal cell toxicity, intestinal toxicity, skin toxicity, tumor cell toxicity, and stem cell toxicity testing.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

HemoGenix® is listed as a fully compliant Contract Research Service Supplier through Scientist.com, a major pharmaceutical outsourcing marketplace. Biopharmaceutical companies use Scientist.com to connect with HemoGenix® and receive quotes through the platform.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

HemoGenix® contract research services are also available through the Science Exchange platform, providing additional channel access for clients seeking in vitro toxicity testing services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Preferred Cell Systems™ is a sister company of HemoGenix® that sells the same proprietary assay platforms as assay kits ('Assays-in-a-Box™') for customers who prefer to perform in-house testing. HemoGenix® and Preferred Cell Systems™ share the same proprietary ATP bioluminescence technology and assay platforms. Preferred Cell Systems™ helps customers establish assays in-house and also licenses the assays.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

HemoGenix® is listed with 100% ratings on the Thermo Fisher Scientific Service Marketplace, which provides an additional platform channel for customers to discover and engage with HemoGenix® contract research services.

Strategic tierModerateTypeStrategic or Co-development Partner
Description

The NCI NCL established an assay cascade for testing nanoparticles used for clinical purposes. HemoGenix® provides superior alternative assays to many of the NCL-recommended assays, using primary human cells rather than animal cells or transformed cell lines. This represents a scientific validation and reference partnership.

Strategic tierModerateTypeTechnology or Integration
Description

HemoGenix® assay platforms use Promega products as signal detection reagents, including CellTiter-Glo® (ATP bioluminescence), GSH-Glo™ (glutathione assay), ROS-Glo™ (reactive oxygen species), Mitochondrial ToxGlo™, CaspaseGlo™, PDE-Glo™, Pgp-Glo™, and ADCC Reporter Bioassay. Promega's luciferase-based reagents form the detection backbone of all HemoGenix® proprietary assays.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

One of the largest clinical and preclinical CROs with extensive in vitro toxicology and central lab services. Comparable as a full-service biopharma outsourcing partner, though many multiples larger than Hemogenix.

TypeDirect peer
Description

Specialty preclinical CRO focused on in vitro ADME and toxicity services including hepatotoxicity and cardiotoxicity. Closely comparable to Hemogenix as a specialist in vitro toxicology CRO using cell-based assays for biopharma.

TypeBroad incumbent
Description

Preclinical CRO and research models provider with toxicology and safety assessment services. Comparable as a specialized preclinical CRO serving drug development toxicology needs of biopharma.

TypeBroad incumbent
Description

Global CRO/CDMO providing preclinical toxicology and in vitro services for biopharma. Comparable in delivering outsourced toxicity testing services to biopharma sponsors across multiple geographies.

TypeEmerging player
Description

Supplies cell culture products, assays, and services supporting stem cell research and cell therapy development. Comparable in serving the hematopoietic and cell therapy research market with specialized assays and tools.

TypeBroad incumbent
Description

Global preclinical CRO offering safety assessment, including in vitro toxicology and hematology studies. Comparable as a leading contract toxicology services provider to biopharma, though far broader in scope than Hemogenix's specialty in vitro hematotoxicity focus.

TypeBroad incumbent
Description

Global CDMO and cell therapy services provider with bioassay and cell-based testing capabilities. Comparable in serving cell therapy developers with potency and quality assays, though at much greater scale.

TypeBroad incumbent
Description

Biosafety, toxicology, and cell line characterization services within Merck's Life Science division. Comparable as a biopharma testing services provider, especially in cell-based safety and quality testing.

TypeOthers
Description

Supplies iPSC-derived cell types including iCell Hepatocytes used as input cells for Hemogenix's hepatotoxicity assays. Comparable as an enabler of in vitro toxicology testing through human-relevant cell models.

TypeBroad incumbent
Description

Large bioanalytical and preclinical testing services provider serving pharma. Comparable in offering outsourced laboratory testing for drug development, including cell-based and bioanalytical assays.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature14 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hemogenix®

Contract Research Serviceshemogenix.com

Hemogenix® is a Colorado Springs-based contract research organization that provides proprietary ATP bioluminescence-based in vitro toxicity testing and cell biology services to biopharmaceutical companies, including more than half of the top 50 global biopharma firms.

What Hemogenix® does

Hemogenix® is a contract research organization (CRO) founded in 2000 and headquartered in Colorado Springs, Colorado, specializing in proprietary in vitro toxicity testing and cell biology services for the biopharmaceutical industry. The company's technology is built on Suspension Expansion Culture™ (SEC™) Technology coupled with ATP bioluminescence signal detection (using third-party Promega reagents such as CellTiter-Glo®), and is delivered through eleven tissue- and cell-type-specific assay platforms: HALO®-Tox HT (hematotoxicity), ImmunoGlo™ (immunotoxicity), MSCGlo™-Tox HT (mesenchymal stem cells), HepatoGlo™-Tox HT (hepatotoxicity), CardioGlo™-Tox HT (cardiotoxicity), RenalGlo™-Tox HT (nephrotoxicity), NeuroGlo™-Tox HT (neurotoxicity), SkinGlo™-Tox HT (skin toxicity), EpiGlo™-Tox HT (intestinal toxicity), CellaGlo™-Tox HT (tumor cells), and STEMGlo™-Tox HT (ES/iPS/transformed cell lines). These are integrated into the ComparaTOX™ multi-tissue comparative platform (available in HT and FS formats) and supplemented by HemaToxFlow™ (flow cytometry-based hematotoxicity), cellular therapy potency and QC assays (HALO® SC-IPS, MSCGlo™ SC-IPS, STEMpredict™, HALO® QC, HALO® TE, HALO® PMT), mechanism-of-action studies, IND-enabling assays, and a Nanoparticle In Vitro Toxicity Panel. HALO®-Tox HT and HALO® SC-IPS are validated according to FDA Bioanalytical Method Validation Guidelines, have FDA Master Files, and HALO®-Tox HT shows 82% in vitro-to-in vivo concordance (Olaharski et al., 2009) and validation against the NIH/ICCVAM Registry of Cytotoxicity Prediction Model.

The company serves small, medium, and large biopharmaceutical companies, with disclosed penetration of more than half of the top 50 global biopharma, and reports that study results have been included in numerous FDA IND applications. Customers engage HemoGenix on a fee-for-service contract basis; there is no subscription or recurring revenue model. Three study formats are offered: a customized full-service study with Study Plan, Phase I Draft Report, Phase II Final Report, and QA audit (suitable for IND submissions, billed under multi-year contract structures); a rapid toxicity study delivering raw data and protocol in an Excel workbook (pay-as-you-go); and a high-throughput screening module priced in multiples of 5 compounds per tissue (pay-as-you-go). Distribution is direct (one-on-one consultation, email/phone engagement at contractresearch@hemogenix.com) and indirect, through listing on the Scientist.com and Science Exchange pharmaceutical outsourcing marketplaces and the Thermo Fisher Scientific Service Marketplace.

The company's go-to-market is sales-led and account-based, leveraging peer-reviewed publications, scientific conference presentations (AABB, ISCT, Society of Toxicology, Cord Blood Symposium), white papers, and marketplace presence to reach biopharma procurement and preclinical safety teams. Preferred Cell Systems™ operates as a sister company that sells the same proprietary assay platforms as kit products ("Assays-in-a-Box™") and licenses them to sponsors who prefer in-house testing, extending revenue capture beyond pure service work. The company has received two NCI SBIR grants (2002 and 2005) to develop the HALO®-Tox HT platform and subsequent assay portfolio. Headcount is reported at 1–10 employees and revenue is not publicly disclosed.

Hemogenix® firmographics

Firmographics
Name
Hemogenix®
Legal name
Hemogenix, Inc.
Website
https://hemogenix.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
1–10 employees
Short description
Hemogenix® is a Colorado Springs-based contract research organization that provides proprietary ATP bioluminescence-based in vitro toxicity testing and cell biology services to biopharmaceutical companies, including more than half of the top 50 global biopharma firms.
Ownership category
akta.pro rank

Hemogenix® industry classification

Industry
Product category
Contract Research Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAFAMAC
Hematology & Coagulation Laboratories
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)

Keywords

  • In vitro toxicity testing
  • Contract research services
  • Cell biology assays
  • Drug safety screening
  • Stem cell potency testing

Where Hemogenix® is headquartered

Location

Headquarters

HQ city
Colorado Springs
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Hemogenix® business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Services (CRO): HemoGenix® operates as a Contract Research Organization (CRO) providing fee-for-service in vitro toxicity testing and cell biology research services. Services are delivered through customized study contracts with biopharmaceutical companies, with study formats ranging from rapid toxicity screening reports to complete IND-enabling full-service studies with QA audit. Revenue is generated on a per-study basis with no recurring subscription model.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustomized Full-Service Study Quote
OtherPay-as-you-goRapid Toxicity Study Quote
Unit PricingPay-as-you-goHigh-Throughput Toxicity Screening Quote (ComparaTOX™ HT)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Hemogenix® product offering

Product offering

Core offering

Hemogenix® is a contract research organization that provides in vitro toxicity testing and cell biology research services to biopharmaceutical companies. The company uses proprietary ATP bioluminescence-based assay platforms built on Suspension Expansion Culture™ (SEC™) Technology to deliver high-throughput hematotoxicity, immunotoxicity, hepatotoxicity, cardiotoxicity, neurotoxicity, renal, skin, intestinal, and tumor cell toxicity testing, along with cell therapy quality and potency testing, IND-enabling studies, mechanism of action studies, and nanoparticle toxicity panels.

Product overview

Hemogenix® is a contract research organization specializing in in vitro toxicity testing and cell biology services. The company offers a comprehensive portfolio of proprietary ATP bioluminescence-based assay platforms, with HALO®-Tox HT as the foundational high-throughput hematotoxicity platform launched in 2002. The product ecosystem includes multiple tissue-specific toxicity testing platforms (ImmunoGlo™, MSCGlo™, HepatoGlo™, CardioGlo™, RenalGlo™, NeuroGlo™, SkinGlo™, EpiGlo™, CellaGlo™, STEMGlo™) that share the same standardized ATP bioluminescence readout technology, enabling direct comparison of drug toxicity across different tissues. The ComparaTOX™ Platform integrates all these assays for multi-tissue comparative toxicity screening in HT (high-throughput) and FS (full service) formats. Additional offerings include HemaToxFlow™ for flow cytometric analysis, potency assays (HALO® SC-IPS, MSCGlo™ SC-IPS, STEMGlo™ SC-IPS), quality control assays (STEMpredict™, HALO® QC), mechanism of action studies, nanoparticle toxicity testing, IND-enabling assay services, and in vivo to in vitro testing extensions. The sister company Preferred Cell Systems™ provides assay kits for in-house testing.

Differentiator

Problem solved

Functional benefit

Brands

  • HALO®-Tox HT: Proprietary high-throughput hematotoxicity screening and testing platform using Suspension Expansion Culture™ (SEC™) Technology and ATP bioluminescence
  • HemaToxFlow™
  • ImmunoGlo™
  • ImmunoGlo™-TCP
  • ImmunoGlo™-BCP
  • ImmunoGlo™-MLC
  • MSCGlo™-Tox HT
  • HepatoGlo™-Tox HT
  • NeuroGlo™-Tox HT
  • CardioGlo™-Tox HT
  • RenalGlo™-Tox HT
  • SkinGlo™-Tox HT
  • EpiGlo™-Tox HT
  • ComparaTOX™ Platform
  • STEMGlo™-Tox HT
  • CellaGlo™-Tox HT
  • HALO® SC-IPS
  • MSCGlo™ SC-IPS
  • STEMpredict™
  • HALO® QC
  • HALO® TE
  • HALO® PMT
  • OxyFLOW™

Products and services

  • HALO®-Tox HT Hematotoxicity Testing Proprietary high-throughput hematotoxicity screening and testing platform for stem and progenitor cell toxicity assessment, available in 96- and 384-well formats and validated according to FDA Bioanalytical Method Validation Guidelines.
  • ImmunoGlo™ Immunotoxicity Testing ATP bioluminescence assay platform for immune cell proliferation, T-cell and B-cell specific cytotoxicity testing, and 1- or 2-way mixed lymphocyte reactions used for immunotoxicity screening and testing.
  • HepatoGlo™-Tox HT Hepatotoxicity Testing Proprietary hepatotoxicity testing platform based on ATP bioluminescence readout for drug-induced liver toxicity (DILI) using various hepatocyte sources including iPS-derived and cryopreserved primary cells.
  • CardioGlo™-Tox HT Cardiotoxicity Testing In vitro cardiotoxicity testing platform using ATP bioluminescence to measure cardiomyocyte viability, supporting multiple cardiomyocyte sources and species for high-throughput compound screening.
  • NeuroGlo™-Tox HT Neurotoxicity Testing Proprietary neurotoxicity screening and testing platform using ATP bioluminescence with iPS-derived human neural cells including GABA neurons and motor neurons, available in 96- or 384-well formats.
  • RenalGlo™-Tox HT Renal Toxicity Testing In vitro renal/nephrotoxicity testing platform using ATP bioluminescence with renal epithelial cell types from medulla, glomerulus, distal and proximal tubules, and cortex, supporting multiple species.
  • SkinGlo™-Tox HT Skin Toxicity Testing In vitro skin toxicity testing platform using ATP bioluminescence with dermal fibroblasts and microvascular endothelial cells from multiple species.
  • EpiGlo™-Tox HT Intestinal Toxicity Testing In vitro intestinal/gut toxicity testing platform using ATP bioluminescence for primary human intestinal cell populations including epithelial cells and myofibroblasts.
  • MSCGlo™-Tox HT Mesenchymal Cell Toxicity Testing Standardized and validated ATP bioluminescence toxicity assay specifically designed for mesenchymal stem/stromal cells (MSCs), measuring functional viability based on intracellular ATP for toxicity testing and high-throughput screening.
  • CellaGlo™-Tox HT Tumor Cell Testing In vitro testing platform for drugs affecting tumor cells using ATP bioluminescence technology.
  • STEMGlo™-Tox HT Stem Cell Toxicity Testing In vitro toxicity testing platform for transformed cell lines, embryonic stem (ES) cells, and induced pluripotent stem (iPS) cells using ATP bioluminescence.
  • ComparaTOX™ Multi-Tissue Comparative Toxicity Platform Multi-tissue comparative toxicity testing platform that integrates all Hemogenix ATP bioluminescence-based assays (HALO, ImmunoGlo, MSCGlo, HepatoGlo, CardioGlo, RenalGlo, NeuroGlo, SkinGlo, EpiGlo, CellaGlo, STEMGlo), enabling direct comparison of drug toxicity across different tissues and species. Available in HT and full-service formats.
  • Cell Therapy Quality & Potency Testing Potency and quality testing service for hematopoietic and mesenchymal stem cells, including Identity, Purity, and Strength (SC-IPS) assays for cord blood, bone marrow, and mobilized peripheral blood; validated per FDA and EMA guidelines for regenerative medicine products.
  • IND-Enabling Assay Services Contract research service providing standardized and validated assay results with measurement assurance parameters suitable for IND applications to the FDA. Results from Hemogenix studies have been included in numerous IND applications.
  • Mechanism of Action Studies Comprehensive mechanism of action study services including flow cytometry, membrane integrity assays, micronucleus assay, soft agar assay, chemotaxis/migration assays, cytokine production/release, kinase/protease assays, mitochondrial dysfunction, oxidative stress assays, and CYP450 assays.
  • Nanoparticle In Vitro Toxicity Panel Comprehensive nanoparticle toxicity testing panel providing alternatives to NCI Nanoparticle Characterization Laboratory (NCL) recommended assays, using superior primary human cells instead of animal cells or transformed cell lines.
  • In Vivo to In Vitro Testing Service extending preclinical animal studies by preparing organs and tissues for in vitro culture systems to detect cellular responses not detectable by normal pharmacological tests, achieving approximately 80% concordance with in vivo results.
  • HemaToxFlow™ Flow Cytometric Hematotoxicity Assay In vitro flow cytometric assay for determining potential hematotoxicity of stem and progenitor cells from human and mouse tissues, using CD markers to define specific differentiated cell populations as an alternative to colony-forming cell (CFC) assays.
  • Contract Research Services (CRO) Full-service contract research organization offering customized full-service, rapid toxicity, and high-throughput screening study workflows covering hematotoxicity, immunotoxicity, hepatotoxicity, cardiotoxicity, neurotoxicity, renal toxicity, mesenchymal cell toxicity, intestinal toxicity, skin toxicity, tumor cell toxicity, and stem cell toxicity testing.

Quantifiable outcome

  • 82% concordance between in vitro HALO®-Tox HT IC50 values and in vivo rat toxicity data
  • +4 more outcomes

Companies that use Hemogenix®

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Hemogenix® technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature14 records

Hemogenix® partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, minor and moderate.

  • Scientist.comcoreChannel Partner/ Reseller/ DistributorHemoGenix® is listed as a fully compliant Contract Research Service Supplier through Scientist.com, a major pharmaceutical outsourcing marketplace. Biopharmaceutical companies use Scientist.com to connect with HemoGenix® and receive quotes through the platform.
  • Science ExchangeminorChannel Partner/ Reseller/ DistributorHemoGenix® contract research services are also available through the Science Exchange platform, providing additional channel access for clients seeking in vitro toxicity testing services.
  • Preferred Cell Systems™coreStrategic or Co-development PartnerPreferred Cell Systems™ is a sister company of HemoGenix® that sells the same proprietary assay platforms as assay kits ('Assays-in-a-Box™') for customers who prefer to perform in-house testing. HemoGenix® and Preferred Cell Systems™ share the same proprietary ATP bioluminescence technology and assay platforms. Preferred Cell Systems™ helps customers establish assays in-house and also licenses the assays.
  • Thermo Fisher Scientific (Service Marketplace)minorChannel Partner/ Reseller/ DistributorHemoGenix® is listed with 100% ratings on the Thermo Fisher Scientific Service Marketplace, which provides an additional platform channel for customers to discover and engage with HemoGenix® contract research services.
  • National Cancer Institute (NCI) Nanoparticle Characterization LaboratorymoderateStrategic or Co-development PartnerThe NCI NCL established an assay cascade for testing nanoparticles used for clinical purposes. HemoGenix® provides superior alternative assays to many of the NCL-recommended assays, using primary human cells rather than animal cells or transformed cell lines. This represents a scientific validation and reference partnership.
  • Promega CorporationmoderateTechnology or IntegrationHemoGenix® assay platforms use Promega products as signal detection reagents, including CellTiter-Glo® (ATP bioluminescence), GSH-Glo™ (glutathione assay), ROS-Glo™ (reactive oxygen species), Mitochondrial ToxGlo™, CaspaseGlo™, PDE-Glo™, Pgp-Glo™, and ADCC Reporter Bioassay. Promega's luciferase-based reagents form the detection backbone of all HemoGenix® proprietary assays.

Scale indicators9 records

Recent moves3 records

Expansion highlights6 records

Hemogenix® competitors and assessment

Company assessment

Broad incumbents

  • Labcorp Drug Development (Covance): One of the largest clinical and preclinical CROs with extensive in vitro toxicology and central lab services. Comparable as a full-service biopharma outsourcing partner, though many multiples larger than Hemogenix.
  • Inotiv: Preclinical CRO and research models provider with toxicology and safety assessment services. Comparable as a specialized preclinical CRO serving drug development toxicology needs of biopharma.
  • WuXi AppTec: Global CRO/CDMO providing preclinical toxicology and in vitro services for biopharma. Comparable in delivering outsourced toxicity testing services to biopharma sponsors across multiple geographies.
  • Charles River Laboratories: Global preclinical CRO offering safety assessment, including in vitro toxicology and hematology studies. Comparable as a leading contract toxicology services provider to biopharma, though far broader in scope than Hemogenix's specialty in vitro hematotoxicity focus.
  • Lonza Bioscience: Global CDMO and cell therapy services provider with bioassay and cell-based testing capabilities. Comparable in serving cell therapy developers with potency and quality assays, though at much greater scale.
  • BioReliance (Merck KGaA): Biosafety, toxicology, and cell line characterization services within Merck's Life Science division. Comparable as a biopharma testing services provider, especially in cell-based safety and quality testing.
  • Eurofins Scientific: Large bioanalytical and preclinical testing services provider serving pharma. Comparable in offering outsourced laboratory testing for drug development, including cell-based and bioanalytical assays.

Direct peers

  • Cyprotex (Evotec): Specialty preclinical CRO focused on in vitro ADME and toxicity services including hepatotoxicity and cardiotoxicity. Closely comparable to Hemogenix as a specialist in vitro toxicology CRO using cell-based assays for biopharma.

Emerging players

  • Stemcell Technologies: Supplies cell culture products, assays, and services supporting stem cell research and cell therapy development. Comparable in serving the hematopoietic and cell therapy research market with specialized assays and tools.

Others

  • Cellular Dynamics International (Fujifilm): Supplies iPSC-derived cell types including iCell Hepatocytes used as input cells for Hemogenix's hepatotoxicity assays. Comparable as an enabler of in vitro toxicology testing through human-relevant cell models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Hemogenix® social profiles

Digital presence

Hemogenix® financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hemogenix® leadership team

Management profile

Number of profiles

Profiles1 record

Hemogenix® subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Hemogenix® funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hemogenix® M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemogenix®

What does Hemogenix® do?

Hemogenix® is a contract research organization that provides in vitro toxicity testing and cell biology research services to biopharmaceutical companies. The company uses proprietary ATP bioluminescence-based assay platforms built on Suspension Expansion Culture™ (SEC™) Technology to deliver high-throughput hematotoxicity, immunotoxicity, hepatotoxicity, cardiotoxicity, neurotoxicity, renal, skin, intestinal, and tumor cell toxicity testing, along with cell therapy quality and potency testing, IND-enabling studies, mechanism of action studies, and nanoparticle toxicity panels.

Is Hemogenix® a public or private company?

Hemogenix® is a private company. It is classified as unknown and is currently operating.

When was Hemogenix® founded?

Hemogenix® was founded in 2000. It employs 1 to 10 people.

Where is Hemogenix® based?

Hemogenix® is headquartered in Colorado Springs, United States, in the North America region.

How does Hemogenix® make money?

One revenue line is on record: contract Research Services (CRO).

Who are Hemogenix®'s main competitors?

Broad incumbents on record are Labcorp Drug Development (Covance), Inotiv, WuXi AppTec, Charles River Laboratories, Lonza Bioscience, BioReliance (Merck KGaA) and Eurofins Scientific. Cyprotex (Evotec) is listed as a direct peer. Stemcell Technologies is listed as an emerging player. Cellular Dynamics International (Fujifilm) is listed as an others.

Does Hemogenix® have an API?

No public API is recorded for Hemogenix®.

What industry is Hemogenix® in?

Hemogenix®'s product category is Contract Research Services. Its primary akta.pro industry code is HLAFAMAC, Hematology & Coagulation Laboratories, with a secondary code of HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales